NCT06836440 (CLEVER) is a NA clinical trial of Free Prescription Glasses in Cognition Disorders, sponsored by Yuju Wu.

Who is sponsoring NCT06836440?

NCT06836440 is sponsored by Yuju Wu.

What drugs are being tested in NCT06836440?

Interventions in NCT06836440: Free Prescription Glasses.

What condition does NCT06836440 study?

NCT06836440 studies Cognition Disorders.

Is NCT06836440 still recruiting?

NCT06836440 is currently recruiting now. Last updated 27 February 2026.

Last reviewed 2026-02-27 · How we verify

NCT06836440: CLEVER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Glasses for Vision Problems on Cognitive Function in Rural Older Adults

Recruiting now NA Last updated 27 February 2026

What this trial tests

NA trial testing Free Prescription Glasses in Cognition Disorders in 964 participants. Currently enrolling.

Timeline

10 November 2025

Primary endpoint
31 December 2028

31 December 2030

Quick facts

Lead sponsor	Yuju Wu
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	964
Start date	10 November 2025
Primary completion	31 December 2028
Estimated completion	31 December 2030
Sites	1 location across China

Drugs / interventions tested

Free Prescription Glasses

Conditions studied

Cognition Disorders — all drugs for Cognition Disorders →

Sponsor

Yuju Wu

Who can join

Adults 60 to 79, any sex, with Cognition Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this project is to explore whether vision correction can effectively slow cognitive decline in older adults. The primary question it seeks to answer is: Can providing free near and/or distance vision correction glasses to older adults with refractive errors or uncorrected vision, who have normal baseline cognition and hearing, reduce the rate of cognitive decline over 36 months in a cost-effective manner? Researchers will compare the rate of cognitive decline over 36 months between older adults who receive refractive correction and those who do not.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cognition Disorders

Currently open trials in the same condition.

NCT07526740 — Brain Stimulation and Cognitive Training for MCI · NA · recruiting

Other Yuju Wu trials

Trials by the same sponsor.

NCT06869031 — Adaptive Intervention Model for Hypertension Self-Management in Rural Areas: A Doctor-Patient Interaction Approach · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06836440 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yuju Wu
Last refreshed: 27 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06836440.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing